<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00672620</url>
  </required_header>
  <id_info>
    <org_study_id>LuAA21004_304</org_study_id>
    <secondary_id>U1111-1114-3497</secondary_id>
    <nct_id>NCT00672620</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Referenced, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily
      (QD), in adults with major depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested
      to treat depression in adults who have major depressive disorder (MDD). This study looked at
      MDD relief in people who took varying dosages of vortioxetine.

      The study enrolled 611 patients. Participants were randomly assigned (by chance, like
      flipping a coin) to one of the four treatment groups—which remained undisclosed to the
      patient and study doctor during the study (unless there was an urgent medical need):

        -  Vortioxetine 2.5 mg

        -  Vortioxetine 5 mg

        -  Duloxetine 10 mg

        -  Placebo (dummy inactive capsule) - this was a capsule that looked like the study drug
           but had no active ingredient.

      All participants were asked to take one capsule at the same time each day throughout the
      study.

      This multi-center trial was conducted in the United States. The overall time to participate
      in this study was up to 12 weeks. Participants made 8 visits to the clinic, and were
      contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with terms for treatment and center as factors and the Baseline rank value as a covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, and 6</time_frame>
    <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with terms for treatment and center as factors and the Baseline rank value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Responders in HAM-D 24 Total Score by Study Visit</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8.</time_frame>
    <description>A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a Sustained Response in HAM-D24</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>A sustained response is defined as a ≥ 20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in MADRS Remission at Week 8</measure>
    <time_frame>Week 8</time_frame>
    <description>Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8</time_frame>
    <description>The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression Scale-Global Improvement Scale</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8.</time_frame>
    <description>The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)</measure>
    <time_frame>Baseline and Weeks 1, 4 and 8</time_frame>
    <description>The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8.</time_frame>
    <description>The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where &lt;17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale</measure>
    <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8.</time_frame>
    <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">611</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Vortioxetine 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine 60 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Encapsulated vortioxetine immediate-release tablets</description>
    <arm_group_label>Vortioxetine 2.5 mg</arm_group_label>
    <arm_group_label>Vortioxetine 5 mg</arm_group_label>
    <other_name>Lu AA21004</other_name>
    <other_name>Brintellix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Duloxetine capsules</description>
    <arm_group_label>Duloxetine 60 mg</arm_group_label>
    <other_name>Cymbalta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo-matching capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suffers from a major depressive episode as the primary diagnosis according to
             Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision
             (DSM-IV-TR) criteria.

          -  The reported duration of the current major depressive episode is at least 3 months.

        Exclusion Criteria:

          -  Has 1 or more the following:

               -  Any current psychiatric disorder other than major depressive disorder as defined
                  in the DSM-IV-TR.

               -  Current or past history of: manic or hypomanic episode, schizophrenia, or any
                  other psychotic disorder, including major depression with psychotic features,
                  mental retardation, organic mental disorders, or mental disorders due to a
                  general medical condition as defined in the DSM-IV-TR.

               -  Any substance disorder (except nicotine and caffeine) within the previous 6
                  months as defined in the DSM-IV-TR.

               -  Presence or history of a clinically significant neurological disorder (including
                  epilepsy).

               -  Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple
                  sclerosis, Huntington disease, etc).

               -  Any Axis II disorder that might compromise the study.

          -  Has a significant risk of suicide according to the investigator's opinion or has a
             score ≥5 on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating
             Scale (MADRS) or has made a suicide attempt in the previous 6 months.

          -  The current depressive symptoms of the patient are considered by the investigator to
             have been resistant to 2 adequate antidepressant treatments of at least 6 weeks
             duration each.

          -  Has received electroconvulsive therapy within 6 months prior to Screening.

          -  Is currently receiving formal cognitive or behavioral therapy, systematic
             psychotherapy, or plans to initiate such therapy during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine,</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Upland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Springs,</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Walton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami,</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago,</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro,</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester,</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olean</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City,</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allenton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City,</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013 Mar;29(3):217-26. doi: 10.1185/03007995.2012.761600. Epub 2013 Jan 17.</citation>
    <PMID>23252878</PMID>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2008</study_first_submitted>
  <study_first_submitted_qc>May 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2008</study_first_posted>
  <results_first_submitted>October 25, 2013</results_first_submitted>
  <results_first_submitted_qc>October 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 18, 2013</results_first_posted>
  <last_update_submitted>October 25, 2013</last_update_submitted>
  <last_update_submitted_qc>October 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Depression</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Major Depressive Episode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 47 investigative sites in the United States from 10 April 2008 to 30 December 2008.</recruitment_details>
      <pre_assignment_details>Participants with a diagnosis of major depressive disorder were enrolled equally in 1 of 4 treatment groups, once a day placebo, 2.5 mg, 5 mg vortioxetine, or 60 mg duloxetine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Vortioxetine 2.5 mg</title>
          <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
        </group>
        <group group_id="P3">
          <title>Vortioxetine 5 mg</title>
          <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
        </group>
        <group group_id="P4">
          <title>Duloxetine 60 mg</title>
          <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="153"/>
                <participants group_id="P2" count="153"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="149"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="150"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="122"/>
                <participants group_id="P4" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviations</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Vortioxetine 2.5 mg</title>
          <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
        </group>
        <group group_id="B3">
          <title>Vortioxetine 5 mg</title>
          <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
        </group>
        <group group_id="B4">
          <title>Duloxetine 60 mg</title>
          <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="153"/>
            <count group_id="B2" value="153"/>
            <count group_id="B3" value="153"/>
            <count group_id="B4" value="152"/>
            <count group_id="B5" value="611"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.6" spread="13.76"/>
                    <measurement group_id="B2" value="42.6" spread="12.85"/>
                    <measurement group_id="B3" value="43.1" spread="13.89"/>
                    <measurement group_id="B4" value="42.7" spread="14.38"/>
                    <measurement group_id="B5" value="42.7" spread="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≤55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="106"/>
                    <measurement group_id="B4" value="91"/>
                    <measurement group_id="B5" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Number of participants for whom Race data were available were 153, 153, 151 and 151 respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian (White, including Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="111"/>
                    <measurement group_id="B5" value="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian/ Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Number of participants for whom Ethnicity data were available were 153, 153, 152 and 151 respectively.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hispanic/Non-Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="133"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="153"/>
                    <measurement group_id="B4" value="152"/>
                    <measurement group_id="B5" value="611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84.22" spread="20.144"/>
                    <measurement group_id="B2" value="85.08" spread="24.126"/>
                    <measurement group_id="B3" value="88.61" spread="25.779"/>
                    <measurement group_id="B4" value="87.44" spread="20.695"/>
                    <measurement group_id="B5" value="86.34" spread="22.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168.98" spread="9.141"/>
                    <measurement group_id="B2" value="169.50" spread="9.385"/>
                    <measurement group_id="B3" value="167.98" spread="9.833"/>
                    <measurement group_id="B4" value="170.37" spread="9.624"/>
                    <measurement group_id="B5" value="169.21" spread="9.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.58" spread="7.263"/>
                    <measurement group_id="B2" value="29.48" spread="7.479"/>
                    <measurement group_id="B3" value="31.38" spread="8.846"/>
                    <measurement group_id="B4" value="30.14" spread="6.773"/>
                    <measurement group_id="B5" value="30.15" spread="7.649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="48"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Once monthly or less often</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Once per week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-to-6 times/week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-item Hamilton Depression Scale total score</title>
          <description>The 24-item Hamilton Depression Scale (HAM-D24) is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="6.05"/>
                    <measurement group_id="B2" value="29.8" spread="5.42"/>
                    <measurement group_id="B3" value="29.8" spread="5.58"/>
                    <measurement group_id="B4" value="28.7" spread="5.08"/>
                    <measurement group_id="B5" value="29.5" spread="5.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery Åsberg Depression Rating Scale (MADRS) total score</title>
          <description>The Montgomery Åsberg Depression Rating Scale (MADRS) is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.0" spread="4.39"/>
                    <measurement group_id="B2" value="29.8" spread="4.61"/>
                    <measurement group_id="B3" value="30.1" spread="4.51"/>
                    <measurement group_id="B4" value="29.4" spread="4.31"/>
                    <measurement group_id="B5" value="29.8" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Anxiety Scale Total Score</title>
          <description>Hamilton Anxiety Scale (HAM-A) is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.8" spread="5.53"/>
                    <measurement group_id="B2" value="19.3" spread="5.22"/>
                    <measurement group_id="B3" value="18.7" spread="5.74"/>
                    <measurement group_id="B4" value="17.4" spread="5.47"/>
                    <measurement group_id="B5" value="18.5" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impression - Severity scale score</title>
          <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="0.62"/>
                    <measurement group_id="B2" value="4.6" spread="0.62"/>
                    <measurement group_id="B3" value="4.6" spread="0.65"/>
                    <measurement group_id="B4" value="4.5" spread="0.67"/>
                    <measurement group_id="B5" value="4.5" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8</title>
        <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with terms for treatment and center as factors and the Baseline rank value as a covariate.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>The full analysis set (FAS) included all randomized patients who received at least 1 dose of study drug and had at least 1 valid postbaseline value for assessment of primary efficacy. Last observation carried forward (LOCF) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8</title>
          <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with terms for treatment and center as factors and the Baseline rank value as a covariate.</description>
          <population>The full analysis set (FAS) included all randomized patients who received at least 1 dose of study drug and had at least 1 valid postbaseline value for assessment of primary efficacy. Last observation carried forward (LOCF) was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.50" spread="0.757"/>
                    <measurement group_id="O2" value="-12.04" spread="0.744"/>
                    <measurement group_id="O3" value="-11.08" spread="0.737"/>
                    <measurement group_id="O4" value="-13.47" spread="0.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>All statistical tests were 2-sided with 95% confidence intervals (CIs), and with P-values evaluated at the 5% significance level (ie, statistical significance if P&lt;0.05). To control for multiplicity, a pre-specified sequential testing procedure was applied to compare 5 mg and 2.5 mg vortioxetine to placebo; as soon as an endpoint was non-significant at 0.05, the testing procedure stopped for all subsequent endpoints.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.577</p_value>
            <p_value_desc>Pre-specified sequential statistical testing procedure indicates that when p-value &gt;0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors, baseline HAM-D24 as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.58</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.036</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.61</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.138</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors, baseline HAM-D24 as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-1.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.038</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.58</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with treatment and center as fixed factors, baseline HAM-D24 as covariate.</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-2.96</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.047</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.02</ci_lower_limit>
            <ci_upper_limit>-0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed</title>
        <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with terms for treatment and center as factors and the Baseline rank value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, and 6</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed</title>
          <description>The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with terms for treatment and center as factors and the Baseline rank value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=142, 143, 150, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="0.515"/>
                    <measurement group_id="O2" value="-5.44" spread="0.497"/>
                    <measurement group_id="O3" value="-5.28" spread="0.491"/>
                    <measurement group_id="O4" value="-5.66" spread="0.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.19" spread="0.567"/>
                    <measurement group_id="O2" value="-7.95" spread="0.557"/>
                    <measurement group_id="O3" value="-7.99" spread="0.552"/>
                    <measurement group_id="O4" value="-8.42" spread="0.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.39" spread="0.663"/>
                    <measurement group_id="O2" value="-9.94" spread="0.651"/>
                    <measurement group_id="O3" value="-8.96" spread="0.645"/>
                    <measurement group_id="O4" value="-10.88" spread="0.657"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.43" spread="0.706"/>
                    <measurement group_id="O2" value="-11.21" spread="0.694"/>
                    <measurement group_id="O3" value="-10.97" spread="0.687"/>
                    <measurement group_id="O4" value="-12.78" spread="0.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Responders in HAM-D 24 Total Score by Study Visit</title>
        <description>A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Responders in HAM-D 24 Total Score by Study Visit</title>
          <description>A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=142, 143, 150, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="8.4"/>
                    <measurement group_id="O3" value="8.7"/>
                    <measurement group_id="O4" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="17.1"/>
                    <measurement group_id="O3" value="17.6"/>
                    <measurement group_id="O4" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="30.8"/>
                    <measurement group_id="O3" value="24.2"/>
                    <measurement group_id="O4" value="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="37.7"/>
                    <measurement group_id="O3" value="37.3"/>
                    <measurement group_id="O4" value="47.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.2"/>
                    <measurement group_id="O2" value="41.1"/>
                    <measurement group_id="O3" value="37.9"/>
                    <measurement group_id="O4" value="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a Sustained Response in HAM-D24</title>
        <description>A sustained response is defined as a ≥ 20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Full analysis set with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a Sustained Response in HAM-D24</title>
          <description>A sustained response is defined as a ≥ 20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.</description>
          <population>Full analysis set with available data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1"/>
                    <measurement group_id="O2" value="15.8"/>
                    <measurement group_id="O3" value="17.0"/>
                    <measurement group_id="O4" value="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in MADRS Remission at Week 8</title>
        <description>Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.</description>
        <time_frame>Week 8</time_frame>
        <population>Full analysis set; LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in MADRS Remission at Week 8</title>
          <description>Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.</description>
          <population>Full analysis set; LOCF was used.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8"/>
                    <measurement group_id="O2" value="28.8"/>
                    <measurement group_id="O3" value="23.5"/>
                    <measurement group_id="O4" value="37.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score</title>
        <description>The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=142, 143, 150, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.90" spread="0.530"/>
                    <measurement group_id="O2" value="-5.16" spread="0.511"/>
                    <measurement group_id="O3" value="-5.06" spread="0.505"/>
                    <measurement group_id="O4" value="-5.49" spread="0.514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.57" spread="0.615"/>
                    <measurement group_id="O2" value="-7.71" spread="0.605"/>
                    <measurement group_id="O3" value="-7.81" spread="0.599"/>
                    <measurement group_id="O4" value="-8.95" spread="0.609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.66" spread="0.693"/>
                    <measurement group_id="O2" value="-9.58" spread="0.681"/>
                    <measurement group_id="O3" value="-9.35" spread="0.675"/>
                    <measurement group_id="O4" value="-11.34" spread="0.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.04" spread="0.770"/>
                    <measurement group_id="O2" value="-11.25" spread="0.757"/>
                    <measurement group_id="O3" value="-11.27" spread="0.750"/>
                    <measurement group_id="O4" value="-13.29" spread="0.763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.22" spread="0.819"/>
                    <measurement group_id="O2" value="-11.61" spread="0.805"/>
                    <measurement group_id="O3" value="-11.30" spread="0.797"/>
                    <measurement group_id="O4" value="-14.10" spread="0.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression Scale-Global Improvement Scale</title>
        <description>The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression Scale-Global Improvement Scale</title>
          <description>The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=142, 143, 149, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.54" spread="0.067"/>
                    <measurement group_id="O2" value="3.42" spread="0.065"/>
                    <measurement group_id="O3" value="3.46" spread="0.064"/>
                    <measurement group_id="O4" value="3.31" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" spread="0.077"/>
                    <measurement group_id="O2" value="3.17" spread="0.076"/>
                    <measurement group_id="O3" value="3.10" spread="0.075"/>
                    <measurement group_id="O4" value="2.99" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="0.085"/>
                    <measurement group_id="O2" value="2.93" spread="0.084"/>
                    <measurement group_id="O3" value="2.87" spread="0.083"/>
                    <measurement group_id="O4" value="2.73" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="0.091"/>
                    <measurement group_id="O2" value="2.82" spread="0.090"/>
                    <measurement group_id="O3" value="2.74" spread="0.089"/>
                    <measurement group_id="O4" value="2.50" spread="0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="0.098"/>
                    <measurement group_id="O2" value="2.73" spread="0.096"/>
                    <measurement group_id="O3" value="2.63" spread="0.095"/>
                    <measurement group_id="O4" value="2.39" spread="0.097"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)</title>
        <description>The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 4 and 8</time_frame>
        <population>Full analysis set with available data at Baseline; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)</title>
          <description>The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set with available data at Baseline; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="145"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=141, 142, 149, 146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="0.310"/>
                    <measurement group_id="O2" value="-2.43" spread="0.299"/>
                    <measurement group_id="O3" value="-2.74" spread="0.295"/>
                    <measurement group_id="O4" value="-2.88" spread="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (148, 145, 152, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.02" spread="0.348"/>
                    <measurement group_id="O2" value="-3.65" spread="0.342"/>
                    <measurement group_id="O3" value="-3.69" spread="0.338"/>
                    <measurement group_id="O4" value="-4.89" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=148, 145, 152, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.25" spread="0.370"/>
                    <measurement group_id="O2" value="-3.98" spread="0.364"/>
                    <measurement group_id="O3" value="-4.04" spread="0.360"/>
                    <measurement group_id="O4" value="-5.70" spread="0.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score</title>
        <description>The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score</title>
          <description>The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where &lt;17 indicates mild severity, 18–24 mild to moderate severity and 25–30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=142, 143, 150, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.63" spread="0.356"/>
                    <measurement group_id="O2" value="-2.98" spread="0.343"/>
                    <measurement group_id="O3" value="-2.55" spread="0.339"/>
                    <measurement group_id="O4" value="-2.30" spread="0.346"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.82" spread="0.419"/>
                    <measurement group_id="O2" value="-4.41" spread="0.412"/>
                    <measurement group_id="O3" value="-3.76" spread="0.408"/>
                    <measurement group_id="O4" value="-3.94" spread="0.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.12" spread="0.457"/>
                    <measurement group_id="O2" value="-5.10" spread="0.450"/>
                    <measurement group_id="O3" value="-4.25" spread="0.445"/>
                    <measurement group_id="O4" value="-4.88" spread="0.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.84" spread="0.482"/>
                    <measurement group_id="O2" value="-5.77" spread="0.474"/>
                    <measurement group_id="O3" value="-4.89" spread="0.469"/>
                    <measurement group_id="O4" value="-6.15" spread="0.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.75" spread="0.502"/>
                    <measurement group_id="O2" value="-5.91" spread="0.494"/>
                    <measurement group_id="O3" value="-5.29" spread="0.488"/>
                    <measurement group_id="O4" value="-6.56" spread="0.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale</title>
        <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Weeks 1, 2, 4, 6 and 8.</time_frame>
        <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale</title>
          <description>The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set; LOCF was used. &quot;n&quot; indicates the number of patients included in the analysis at each time point.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=142, 143, 150, 147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.055"/>
                    <measurement group_id="O2" value="-0.40" spread="0.053"/>
                    <measurement group_id="O3" value="-0.37" spread="0.053"/>
                    <measurement group_id="O4" value="-0.44" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.071"/>
                    <measurement group_id="O2" value="-0.65" spread="0.069"/>
                    <measurement group_id="O3" value="-0.66" spread="0.069"/>
                    <measurement group_id="O4" value="-0.75" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.92" spread="0.086"/>
                    <measurement group_id="O2" value="-0.92" spread="0.085"/>
                    <measurement group_id="O3" value="-0.90" spread="0.084"/>
                    <measurement group_id="O4" value="-1.12" spread="0.085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.11" spread="0.094"/>
                    <measurement group_id="O2" value="-1.08" spread="0.092"/>
                    <measurement group_id="O3" value="-1.08" spread="0.091"/>
                    <measurement group_id="O4" value="-1.39" spread="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=149, 146, 153, 149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="0.103"/>
                    <measurement group_id="O2" value="-1.21" spread="0.102"/>
                    <measurement group_id="O3" value="-1.17" spread="0.101"/>
                    <measurement group_id="O4" value="-1.56" spread="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8</title>
        <description>The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full analysis set with available data at Baseline; LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8</title>
          <description>The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.</description>
          <population>Full analysis set with available data at Baseline; LOCF was used.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="122"/>
                <count group_id="O3" value="123"/>
                <count group_id="O4" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.83" spread="0.638"/>
                    <measurement group_id="O2" value="-6.46" spread="0.640"/>
                    <measurement group_id="O3" value="-6.59" spread="0.641"/>
                    <measurement group_id="O4" value="-8.91" spread="0.672"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire</title>
        <description>Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine 2.5 mg</title>
            <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O3">
            <title>Vortioxetine 5 mg</title>
            <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
          </group>
          <group group_id="O4">
            <title>Duloxetine 60 mg</title>
            <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
          </group>
        </group_list>
        <measure>
          <title>Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire</title>
          <description>Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.</description>
          <population>Full analysis set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="149"/>
                <count group_id="O2" value="146"/>
                <count group_id="O3" value="153"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Any resource use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Any hospitalization-related services</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Hospitalization related to depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Any sick leave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Sick leave related to depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Any resource use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Any hospitalization-related service</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Hospitalization related to depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Any sick leave</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Sick leave related to depression</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the 8-week treatment period and a 4-week follow-up period.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo-matching capsules, orally, once daily for up to 9 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Vortioxetine 2.5 mg</title>
          <description>Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
        </group>
        <group group_id="E3">
          <title>Vortioxetine 5 mg</title>
          <description>Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.</description>
        </group>
        <group group_id="E4">
          <title>Duloxetine 60 mg</title>
          <description>Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Feeling jittery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="150"/>
              </event>
              <event>
                <sub_title>Orgasm abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="149"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="153"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="150"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

